Cargando…
Chimeric antigen receptor modified T-cells for cancer treatment
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Medical Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309024/ https://www.ncbi.nlm.nih.gov/pubmed/30603741 http://dx.doi.org/10.1016/j.cdtm.2018.08.002 |
_version_ | 1783383326036328448 |
---|---|
author | Han, Xiao Wang, Yao Han, Wei-Dong |
author_facet | Han, Xiao Wang, Yao Han, Wei-Dong |
author_sort | Han, Xiao |
collection | PubMed |
description | T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR-T cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR-T in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR-T cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR-T and some novel CAR designs, the clinical application of CAR-T cell therapies, as well as the assessment and management of toxicities. |
format | Online Article Text |
id | pubmed-6309024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Chinese Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-63090242019-01-02 Chimeric antigen receptor modified T-cells for cancer treatment Han, Xiao Wang, Yao Han, Wei-Dong Chronic Dis Transl Med Perspective T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR-T cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR-T in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR-T cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR-T and some novel CAR designs, the clinical application of CAR-T cell therapies, as well as the assessment and management of toxicities. Chinese Medical Association 2018-09-18 /pmc/articles/PMC6309024/ /pubmed/30603741 http://dx.doi.org/10.1016/j.cdtm.2018.08.002 Text en © 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Perspective Han, Xiao Wang, Yao Han, Wei-Dong Chimeric antigen receptor modified T-cells for cancer treatment |
title | Chimeric antigen receptor modified T-cells for cancer treatment |
title_full | Chimeric antigen receptor modified T-cells for cancer treatment |
title_fullStr | Chimeric antigen receptor modified T-cells for cancer treatment |
title_full_unstemmed | Chimeric antigen receptor modified T-cells for cancer treatment |
title_short | Chimeric antigen receptor modified T-cells for cancer treatment |
title_sort | chimeric antigen receptor modified t-cells for cancer treatment |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309024/ https://www.ncbi.nlm.nih.gov/pubmed/30603741 http://dx.doi.org/10.1016/j.cdtm.2018.08.002 |
work_keys_str_mv | AT hanxiao chimericantigenreceptormodifiedtcellsforcancertreatment AT wangyao chimericantigenreceptormodifiedtcellsforcancertreatment AT hanweidong chimericantigenreceptormodifiedtcellsforcancertreatment |